Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma.
Peter J. Allen,Deborah Kuk,Carlos Fernandez-del Castillo,Olca Basturk,Christopher L. Wolfgang,John L. Cameron,Keith D. Lillemoe,Cristina R. Ferrone,Vicente Morales-Oyarvide,Jin He,Matthew J. Weiss,Ralph H. Hruban,Mithat Gonen,David S. Klimstra,Mari Mino-Kenudson +14 more
Reads0
Chats0
TLDR
The proposed 8th edition changes for T and N classification were statistically valid and may allow a more reproducible system of T staging, which stratifies patients more evenly across stages without sacrificing prognostic accuracy.Abstract:
Objective:The aim of this study was to evaluate and validate the proposed 8th edition American Joint Committee on Cancer (AJCC) system for T and N staging of pancreatic adenocarcinoma.Summary of Background Data:Investigators have questioned the clinical relevance and reproducibility of previous AJCCread more
Citations
More filters
Journal ArticleDOI
8th Edition of the AJCC Cancer Staging Manual: Pancreas and Hepatobiliary Cancers
TL;DR: For the new 8th edition of the AJCC Staging Manual, the N category has been harmonized for gallbladder, perihilar bile ducts, distal biles duct, ampulla, and pancreas, and a number-based categorization of metastatic lymph nodes results in better prognostic stratification.
Journal ArticleDOI
Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers
Joshua D. Cohen,Ammar A. Javed,Christopher J. Thoburn,Fay Wong,Jeanne Tie,Jeanne Tie,Peter Gibbs,Peter Gibbs,C. Max Schmidt,Michele T. Yip-Schneider,Peter J. Allen,Mark A. Schattner,Randall E. Brand,Aatur D. Singhi,Gloria M. Petersen,Seung-Mo Hong,Song Cheol Kim,Massimo Falconi,Claudio Doglioni,Matthew J. Weiss,Nita Ahuja,Jin He,Martin A. Makary,Anirban Maitra,Samir M. Hanash,Marco Dal Molin,Yuxuan Wang,Lu Li,Janine Ptak,Lisa Dobbyn,Joy Schaefer,Natalie Silliman,Maria Popoli,Michael Goggins,Ralph H. Hruban,Christopher L. Wolfgang,Alison P. Klein,Cristian Tomasetti,Nickolas Papadopoulos,Kenneth W. Kinzler,Bert Vogelstein,Anne Marie Lennon +41 more
TL;DR: It is shown how combining mutations in circulating tumor DNA (ctDNA) with protein markers can result in a screening test with improved sensitivity while retaining specificity, which may prove useful for the earlier detection of many cancer types.
Journal ArticleDOI
International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017
Shuji Isaji,Shugo Mizuno,John A. Windsor,Claudio Bassi,Carlos Fernandez-del Castillo,Thilo Hackert,Aoi Hayasaki,Matthew H.G. Katz,Sun Whe Kim,Masashi Kishiwada,Hirohisa Kitagawa,Christoph W. Michalski,Christopher L. Wolfgang +12 more
TL;DR: The present definition acknowledges that resectability is not just about the anatomic relationship between the tumor and vessels, but that biological and conditional dimensions are also important.
Journal ArticleDOI
Pancreatic Cancer: A Review
TL;DR: In this article, a multidisciplinary management approach is recommended for PDAC patients, which includes a multi-agent chemotherapy regimens, including FOLFIRINOX, gemcitabine/nab-paclitaxel, and nanoliposomal irinotecan/fluorouracil.
Journal ArticleDOI
Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations
Zishuo I. Hu,Jinru Shia,Jinru Shia,Zsofia K. Stadler,Zsofia K. Stadler,Anna M. Varghese,Anna M. Varghese,Marinela Capanu,Erin E. Salo-Mullen,Maeve A. Lowery,Luis A. Diaz,Diana Mandelker,Kenneth H. Yu,Kenneth H. Yu,Alice Zervoudakis,Alice Zervoudakis,David P. Kelsen,David P. Kelsen,Christine A. Iacobuzio-Donahue,Christine A. Iacobuzio-Donahue,David S. Klimstra,David S. Klimstra,Leonard B. Saltz,Leonard B. Saltz,Ibrahim Halil Sahin,Eileen M. O'Reilly,Eileen M. O'Reilly +26 more
TL;DR: An integrated approach of germline testing and somatic analyses of tumor tissues in advanced PDAC using NGS may help guide future development of immune and molecularly directed therapies in PDAC patients.
References
More filters
Book
AJCC Cancer Staging Manual
Mahul B. Amin,Stephen B. Edge,Frederick L. Greene,David R. Byrd,Robert K. Brookland,Mary Kay Washington,Jeffrey E. Gershenwald,Carolyn C. Compton,Kenneth R. Hess,Daniel C. Sullivan,J. Milburn Jessup,James D. Brierley,Lauri E. Gaspar,Richard L. Schilsky,Charles M. Balch,David P. Winchester,Elliot A. Asare,Martin Madera,Donna M. Gress,Laura R. Meyer +19 more
TL;DR: Purposes and Principles of Cancer Staging and End-Results Reporting are explained.
Journal ArticleDOI
Regression modelling strategies for improved prognostic prediction.
TL;DR: A general index of predictive discrimination is used to measure the ability of a model developed on training samples of varying sizes to predict survival in an independent test sample of patients suspected of having coronary artery disease.
Journal ArticleDOI
Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS).
Johanna A. M. G. Tol,Dirk J. Gouma,Claudio Bassi,Christos Dervenis,Marco Montorsi,Mustapha Adham,Åke Andrén-Sandberg,Horacio J. Asbun,Maximilian Bockhorn,Markus W. Büchler,Kevin C. Conlon,Laureano Fernández-Cruz,Abe Fingerhut,Abe Fingerhut,Helmut Friess,Werner Hartwig,Jakob R. Izbicki,Keith D. Lillemoe,Miroslav Milicevic,John P. Neoptolemos,Shailesh V. Shrikhande,Charles M. Vollmer,Charles J. Yeo,Richard Charnley +23 more
TL;DR: Standard lymphadenectomy for pancreatoduodenectomy should strive to resect Ln stations no. 5, 6, 8a, 12b1,12b2, 12c, 13a, 13b, 14a, 14b, 17a, and 17b, for cancers of the body and tail of the pancreas, removal of stations 10, 11, and 18 is standard.
Journal ArticleDOI
The Lymph Node Ratio is the Strongest Prognostic Factor after Resection of Pancreatic Cancer
Hartwig Riediger,Tobias Keck,Ulrich F. Wellner,Axel zur Hausen,Ulrich Adam,Ulrich T. Hopt,Frank Makowiec +6 more
TL;DR: The routine estimation of the LN ratio may be helpful not only for the individual prediction of prognosis but also for the indication of adjuvant therapy and herein related outcome and therapy studies.
Journal ArticleDOI
Survival after Resection of Pancreatic Adenocarcinoma: Results from a Single Institution over Three Decades
Jordan M. Winter,Murray F. Brennan,Laura H. Tang,Michael I. D’Angelica,Ronald P. DeMatteo,Yuman Fong,David S. Klimstra,William R. Jarnagin,Peter J. Allen +8 more
TL;DR: Patients who underwent resection for pancreatic cancer between 2000 and 2009 experienced improved operative mortality and 1-year survival compared to those who underwent re- resection in the 1980s, while the long-term survival was similar over all three decades.
Related Papers (5)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy,Françoise Desseigne,Marc Ychou,Olivier Bouché,Rosine Guimbaud,Yves Becouarn,Antoine Adenis,Jean-Luc Raoul,Sophie Gourgou-Bourgade,Jaafar Bennouna,Jean-Baptiste Bachet,Faiza Khemissa-Akouz,Denis Péré-Vergé,Catherine Delbaldo,Eric Assenat,Bruno Chauffert,C. Montoto-Grillot,Michel Ducreux +17 more
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff,Thomas J. Ervin,Francis P. Arena,E. Gabriela Chiorean,Jeffrey R. Infante,Malcolm J. Moore,Thomas E. Seay,Sergei Tjulandin,Wen Wee Ma,Mansoor N. Saleh,Marion Harris,Michele Reni,Scot Dowden,Daniel A. Laheru,Nathan Bahary,Ramesh K. Ramanathan,Josep Tabernero,Manuel Hidalgo,David Goldstein,Eric Van Cutsem,Xinyu Wei,Jose Iglesias,Markus F. Renschler +22 more